C1-inhibitor: More than a serine protease inhibitor

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 4, 2011, Pages 362-374

  Zeerleder, Sacha ^a,b  

^a SANQUIN RESEARCH   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

C1 inhibitor; complement; contact phase; hereditary angioedema; sepsis; serpin

Indexed keywords

ALPHA INTERFERON; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; ANAPHYLATOXIN; ANTIINFLAMMATORY AGENT; ANTIPLASMIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; BRADYKININ; CINRYCE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C1S INHIBITOR; ENZYME PRECURSOR; FRESH FROZEN PLASMA; GLYCOSAMINOGLYCAN; HIGH MOLECULAR WEIGHT KININOGEN; ICATIBANT; INTERLEUKIN 6; KALLIKREIN; LIPOPOLYSACCHARIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; MANNAN BINDING LECTIN; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREKALLIKREIN; SERINE PROTEINASE INHIBITOR; TRANEXAMIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIGEN ANTIBODY COMPLEX; ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; BIOCHEMISTRY; BIOLOGY; BLOOD CLOTTING; BLOOD CLOTTING FACTOR 11 DEFICIENCY; BLOOD VESSEL PERMEABILITY; CHEMICAL BOND; CHEMOTAXIS; COMPLEMENT SYSTEM; COVALENT BOND; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; CYTOLYSIS; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; EDEMA; ENDOTHELIUM CELL; ENZYME INACTIVATION; ENZYME INHIBITION; EPITHELIUM CELL; FIBRINOLYSIS; FIBROBLAST; GENE MUTATION; GLYCOSYLATION; HISTAMINE RELEASE; HUMAN; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER; LIVER CELL; LOSS OF FUNCTION MUTATION; MACROPHAGE; MEGAKARYOCYTE; MICROGLIA; MOLECULAR WEIGHT; MONOCYTE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; PLASMA HALF LIFE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN STABILITY; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SEQUENCE HOMOLOGY; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOPLASTIN TIME; UNITED STATES;

ANIMALS; COMPLEMENT C1 INHIBITOR PROTEIN; FIBRINOLYSIS; HUMANS;

EID: 79961061340     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1276585     Document Type: Review

References (161)

1. Caliezi C, Wuillemin W A., Zeerleder S, Redondo M, Eisele B, Hack C E. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000 52 1 91-112 (Pubitemid 30127596)
2. Schapira M, de Agostini A, Schifferli J A., Colman R W. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement 1985 2 23 111-126 (Pubitemid 16213813)
3. Nuijens J H., Eerenberg-Belmer A JM, Huijbregts C C. et al. Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest 1989 84 2 443-450 (Pubitemid 19196974)
4. Travis J, Salvesen G S. Human plasma proteinase inhibitors. Annu Rev Biochem 1983 52 655-709 (Pubitemid 13030691)
5. Carrell R W., Boswell D R. Serpins: the superfamily of plasma proteinase inhibitors. In: Barrett A J. Salvesen G eds. Proteinase Inhibitors. Amsterdam, The Netherlands Elsevier 1990 403-420
6. Carrell R W., Travis J. 1-antitrypsin and the serpins: variation and countervariation. Trends Biochem Sci 1985 10 20-24
7. Carter P E., Dunbar B, Fothergill J E. Genomic and cDNA cloning of the human C1 inhibitor. Intron-exon junctions and comparison with other serpins. Eur J Biochem 1988 173 1 163-169
8. Coutinho M, Aulak K S., Davis A E. III. Functional analysis of the serpin domain of C1 inhibitor. J Immunol 1994 153 8 3648-3654 (Pubitemid 24313869)
9. Wagenaar-Bos I G., Hack C E. Structure and function of C1-inhibitor. Immunol Allergy Clin North Am 2006 26 4 615-632 (Pubitemid 44755113)
10. Bock S C., Skriver K, Nielsen E et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986 25 15 4292-4301 (Pubitemid 16054244)
11. Bos I G., Lubbers Y T., Roem D, Abrahams J P., Hack C E., Eldering E. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant. J Biol Chem 2003 278 32 29463-29470 (Pubitemid 36962325)
12. Huntington J A., Read R J., Carrell R W. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000 407 6806 923-926
13. Schapira M, de Agostini A, Colman R W. C1 inhibitor: the predominant inhibitor of plasma kallikrein. Methods Enzymol 1988 163 179-185 (Pubitemid 19043414)
14. Ravindran S, Grys T E., Welch R A., Schapira M, Patston P A. Inhibition of plasma kallikrein by C1-inhibitor: role of endothelial cells and the amino-terminal domain of C1-inhibitor. Thromb Haemost 2004 92 6 1277-1283 (Pubitemid 39642537)
15. Minta J O. The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. J Immunol 1981 126 1 245-249 (Pubitemid 11218911)
16. Reboul A, Prandini M H., Colomb M G. Proteolysis and deglycosylation of human C1 inhibitor. Effect on functional properties. Biochem J 1987 244 1 117-121 (Pubitemid 17098817)
17. van Doorn M B., Burggraaf J, van Dam T et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol 2005 116 4 876-883 (Pubitemid 41400555)
18. Bos I G., de Bruin E C., Karuntu Y A., Modderman P W., Eldering E, Hack C E. Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor. Biochim Biophys Acta 2003 1648 12 75-83 (Pubitemid 38234608)
19. Bensa J C., Reboul A, Colomb M G. Biosynthesis in vitro of complement subcomponents C1q, C1s and C1 inhibitor by resting and stimulated human monocytes. Biochem J 1983 216 2 385-392 (Pubitemid 14244300)
20. Yeung Laiwah A C., Jones L, Hamilton A O., Whaley K. Complement- subcomponent-C1-inhibitor synthesis by human monocytes. Biochem J 1985 226 1 199-205
21. Katz Y, Strunk R C. Synthesis and regulation of C1 inhibitor in human skin fibroblasts. J Immunol 1989 142 6 2041-2045 (Pubitemid 19081561)
22. Katz Y, Gur S, Aladjem M, Strunk R C. Synthesis of complement proteins in amnion. J Clin Endocrinol Metab 1995 80 7 2027-2032
23. Walker D G., Yasuhara O, Patston P A., McGeer E G., McGeer P L. Complement C1 inhibitor is produced by brain tissue and is cleaved in Alzheimer disease. Brain Res 1995 675 12 75-82
24. Lotz M, Zuraw B L. Interferon-gamma is a major regulator of C1-inhibitor synthesis by human blood monocytes. J Immunol 1987 139 10 3382-3387 (Pubitemid 18021991)
25. Zuraw B L., Lotz M. Regulation of the hepatic synthesis of C1 inhibitor by the hepatocyte stimulating factors interleukin 6 and interferon gamma. J Biol Chem 1990 265 21 12664-12670
26. Schmidt B, Gyapay G, Válay M, Füst G. Human recombinant macrophage colony-stimulating factor (M-CSF) increases Cl-esterase inhibitor (Cl-INH) synthesis by human monocytes. Immunology 1991 74 4 677-679
27. Heda G D., Mardente S, Weiner L, Schmaier A H. Interferon increases in vitro and in vivo expression of C1 inhibitor. Blood 1990 75 12 2401-2407 (Pubitemid 20202320)
28. Heda G D., Kehoe K J., Mahdi F, Schmaier A H. Phosphatase 2A participates in interferon-'s induced upregulation of C1 inhibitor mRNA expression. Blood 1996 87 7 2831-2838 (Pubitemid 26104607)
29. Zahedi K, Prada A E., Prada J A., Davis A E. III. Characterization of the IFN - responsive element in the 5 flanking region of the C1 inhibitor gene. J Immunol 1997 159 12 6091-6096 (Pubitemid 127471547)
30. Schmaier A H., Amenta S, Xiong T, Heda G D., Gewirtz A M. Expression of platelet C1 inhibitor. Blood 1993 82 2 465-474 (Pubitemid 23206109)
31. Woo P, Lachmann P JL, Harrison R A., Amos N, Cooper C, Rosen F S. Simultaneous turnover of normal and dysfunctional C1 inhibitor as a probe of in vivo activation of C1 and contact activatable proteases. Clin Exp Immunol 1985 61 1 1-8 (Pubitemid 15029840)
32. Quastel M, Harrison R, Cicardi M, Alper C A., Rosen F S. Behavior in vivo of normal and dysfunctional C1 inhibitor in normal subjects and patients with hereditary angioneurotic edema. J Clin Invest 1983 71 4 1041-1046 (Pubitemid 13163276)
33. de Smet BJGL, de Boer J P., Agterberg J, Rigter G, Bleeker W K., Hack C E. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 1993 81 1 56-61 (Pubitemid 23013677)
34. Pappalardo E, Zingale L C., Cicardi M. C1 inhibitor gene expression in patients with hereditary angioedema: quantitative evaluation by means of real-time RT-PCR. J Allergy Clin Immunol 2004 114 3 638-644 (Pubitemid 39194941)
35. Wuillemin W A., Bleeker W K., Agterberg J, Rigter G, ten Cate H, Hack C E. Clearance of human factor XIa-inhibitor complexes in rats. Br J Haematol 1996 93 4 950-954
36. Nuijens J H., Huijbregts C C., Eerenberg-Belmer A JM et al. Quantification of plasma factor XIIa-Cl(-)-inhibitor and kallikrein-Cl(-)- inhibitor complexes in sepsis. Blood 1988 72 6 1841-1848 (Pubitemid 19030867)
37. Perlmutter D H., Glover G I., Rivetna M, Schasteen C S., Fallon R J. Identification of a serpin-enzyme complex receptor on human hepatoma cells and human monocytes. Proc Natl Acad Sci U S A 1990 87 10 3753-3757
38. Pizzo S V., Mast A E., Feldman S R., Salvesen G. In vivo catabolism of 1-antichymotrypsin is mediated by the Serpin receptor which binds 1-proteinase inhibitor, antithrombin III and heparin cofactor II. Biochim Biophys Acta 1988 967 2 158-162 (Pubitemid 18265671)
39. Kalter E S., Daha M R., ten Cate J W., Verhoef J, Bouma B N. Activation and inhibition of Hageman factor-dependent pathways and the complement system in uncomplicated bacteremia or bacterial shock. J Infect Dis 1985 151 6 1019-1027 (Pubitemid 15065973)
40. Falus A, Rokita H, Walcz E, Brozik M, Hidvégi T, Merétey K. Hormonal regulation of complement biosynthesis in human cell linesII. Upregulation of the biosynthesis of complement components C3, factor B and C1 inhibitor by interleukin-6 and interleukin-1 in human hepatoma cell line. Mol Immunol 1990 27 2 197-201 (Pubitemid 20058773)
41. Brower M S., Harpel P C. Proteolytic cleavage and inactivation of 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982 257 16 9849-9854 (Pubitemid 13205151)
42. Eldering E, Huijbregts C CM, Nuijens J H., Verhoeven A J., Hack C E. Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils. J Clin Invest 1993 91 3 1035-1043 (Pubitemid 23095279)
43. Leid R W., Ballieux BEPB, van der Heijden I et al. Cleavage and inactivation of human C1 inhibitor by the human leukocyte proteinase, proteinase 3. Eur J Immunol 1993 23 11 2939-2944 (Pubitemid 23323572)
44. Wallace E M., Perkins S J., Sim R B., Willis A C., Feighery C, Jackson J. Degradation of C1-inhibitor by plasmin: implications for the control of inflammatory processes. Mol Med 1997 3 6 385-396 (Pubitemid 27353617)
45. Catanese J, Kress L F. Enzymatic inactivation of human plasma C1-inhibitor and 1-antichymotrypsin by Pseudomonas aeruginosa proteinase and elastase. Biochim Biophys Acta 1984 789 1 37-43
46. Zhang F, Bries A D., Lang S C. et al. Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency. Biochim Biophys Acta 2004 1739 1 43-49 (Pubitemid 39647709)
47. Doekes G, van Es L A., Daha M R. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates. Immunology 1983 49 2 215-222 (Pubitemid 13096768)
48. Tenner A J., Frank M M. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. J Immunol 1986 137 2 625-630 (Pubitemid 16045093)
49. Turner M W. Mannose-binding lectin: the pluripotent molecule of the innate immune system. Immunol Today 1996 17 11 532-540 (Pubitemid 26373253)
50. Thiel S, Vorup-Jensen T, Stover C M. et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature 1997 386 6624 506-510 (Pubitemid 27164078)
51. Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med 1992 176 6 1497-1502
52. Matsushita M, Thiel S, Jensenius J C., Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 2000 165 5 2637-2642 (Pubitemid 30660711)
53. Makrides S C. Therapeutic inhibition of the complement system. Pharmacol Rev 1998 50 1 59-87 (Pubitemid 28158842)
54. Podack E R., Kolb W P., Müller-Eberhard H J. The SC5b-7 complex: formation, isolation, properties, and subunit composition. J Immunol 1977 119 6 2024-2029 (Pubitemid 8232100)
55. Tschopp J, Müller-Eberhard H J., Podack E R. Formation of transmembrane tubules by spontaneous polymerization of the hydrophilic complement protein C9. Nature 1982 298 5874 534-538 (Pubitemid 12038654)
56. Hugli T E., Müller-Eberhard H J. Anaphylatoxins: C3a and C5a. Adv Immunol 1978 26 1-53
57. Morgan E L. Modulation of the immune response by anaphylatoxins. Complement 1986 3 3 128-136 (Pubitemid 17208217)
58. Hartmann K, Henz B M., Krüger-Krasagakes S et al. C3a and C5a stimulate chemotaxis of human mast cells. Blood 1997 89 8 2863-2870 (Pubitemid 27172573)
59. Gerard C, Gerard N P. C5A anaphylatoxin and its seven transmembrane-segment receptor. Annu Rev Immunol 1994 12 775-808 (Pubitemid 24140431)
60. Sim R B., Reboul A, Arlaud G J., Villiers C L., Colomb M G. Interaction of 125I-labelled complement subcomponents C-1r and C-1s with protease inhibitors in plasma. FEBS Lett 1979 97 1 111-115 (Pubitemid 9108530)
61. Liszewski M K., Farries T C., Lublin D M., Rooney I A., Atkinson J P. Control of the complement system. Adv Immunol 1996 61 201-283 (Pubitemid 26065042)
62. Bianchino A C., Poon P H., Schumaker V N. A mechanism for the spontaneous activation of the first component of complement, C1, and its regulation by C1-inhibitor. J Immunol 1988 141 11 3930-3936
63. Harpel P C., Cooper N R. Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest 1975 55 3 593-604
64. Reboul A, Arlaud G J., Sim R B., Colomb M G. A simplified procedure for the purification of C1-inactivator from human plasma. Interaction with complement subcomponents C1r and C1s. FEBS Lett 1977 79 1 45-50 (Pubitemid 8163382)
65. Salvesen G S., Catanese J J., Kress L F., Travis J. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem 1985 260 4 2432-2436 (Pubitemid 15104850)
66. Arlaud G J., Reboul A, Sim R B., Colomb M G. Interaction of C1-inhibitor with the C1r and C1s subcomponents in human C1. Biochim Biophys Acta 1979 576 1 151-162 (Pubitemid 9086866)
67. Ziccardi R J., Cooper N R. Active disassembly of the first complement component, C-1, by C-1 inactivator. J Immunol 1979 123 2 788-792 (Pubitemid 9211255)
68. Chesne S, Villiers C L., Arlaud G J., Lacroix M B., Colomb M G. Fluid-phase interaction of C1 inhibitor (C1 Inh) and the subcomponents C1r and C1s of the first component of complement, C1. Biochem J 1982 201 1 61-70
69. Sim R B., Arlaud G J., Colomb M G. Kinetics of reaction of human C1-inhibitor with the human complement system proteases C1r and C1s. Biochim Biophys Acta 1980 612 2 433-449 (Pubitemid 10076173)
70. Jiang H, Wagner E, Zhang H, Frank M M. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001 194 11 1609-1616 (Pubitemid 33126811)
71. Kaplan A P., Silverberg M. The coagulation-kinin pathway of human plasma. Blood 1987 70 1 1-15 (Pubitemid 17111234)
72. Colman R W. Surface-mediated defense reactions. The plasma contact activation system. J Clin Invest 1984 73 5 1249-1253 (Pubitemid 14139518)
73. Cochrane C G., Griffin J H. The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 1982 33 241-306
74. Hojima Y, Cochrane C G., Wiggins R C., Austen K F., Stevens R L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E. Blood 1984 63 6 1453-1459 (Pubitemid 14120394)
75. Kannemeier C, Shibamiya A, Nakazawa F et al. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci U S A 2007 104 15 6388-6393 (Pubitemid 47186104)
76. Maas C, Govers-Riemslag J W., Bouma B et al. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008 118 9 3208-3218
77. Müller F, Mutch N J., Schenk W A. et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009 139 6 1143-1156
78. Herwald H, Mörgelin M, Olsén A et al. Activation of the contact-phase system on bacterial surfacesa clue to serious complications in infectious diseases. Nat Med 1998 4 3 298-302 (Pubitemid 28144087)
79. Colman R W., Bagdasarian A, Talamo R C. et al. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975 56 6 1650-1662
80. Ghebrehiwet B, Randazzo B P., Dunn J T., Silverberg M, Kaplan A P. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983 71 5 1450-1456 (Pubitemid 13098935)
81. Schousboe I. Binding of activated factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem 2003 270 1 111-118 (Pubitemid 36056940)
82. Lämmle B, Wuillemin W A., Huber I et al. Thromboembolism and bleeding tendency in congenital factor XII deficiencya study on 74 subjects from 14 Swiss families. Thromb Haemost 1991 65 2 117-121
83. Pixley R A., De La Cadena R, Page J D. et al. The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin Invest 1993 91 1 61-68 (Pubitemid 23037253)
84. Gailani D, Broze G J. Jr. Factor XI activation in a revised model of blood coagulation. Science 1991 253 5022 909-912 (Pubitemid 21917236)
85. Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991 266 12 7353-7358 (Pubitemid 21906372)
86. Renné T, Pozgajová M, Grüner S et al. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005 202 2 271-281 (Pubitemid 41043823)
87. Wuillemin W A., Minnema M, Meijers J C. et al. Inactivation of factor XIa in human plasma assessed by measuring factor XIa-protease inhibitor complexes: major role for C1-inhibitor. Blood 1995 85 6 1517-1526
88. Wuillemin W A., Hack C E., Bleeker W K., Biemond B J., Levi M, ten Cate H. Inactivation of factor Xia in vivo: studies in chimpanzees and in humans. Thromb Haemost 1996 76 4 549-555 (Pubitemid 26372010)
89. Nielsen E W., Morrissey J, Olsen J O., Osterud B. Factor VIIa in patients with C1-inhibitor deficiency. Thromb Haemost 1995 74 4 1103-1106
90. Nielsen E W., Johansen H T., Høgåsen K, Wuillemin W A., Hack C E., Mollnes T E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema. Scand J Immunol 1996 44 2 185-192 (Pubitemid 26246739)
91. Husain S S., Hasan A AK, Budzynski A Z. Differences between binding of one-chain and two-chain tissue plasminogen activators to non-cross-linked and cross-linked fibrin clots. Blood 1989 74 3 999-1006
92. Vassalli J D., Sappino A P., Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991 88 4 1067-1072
93. Zamarron C, Lijnen H R., Van Hoef B, Collen D. Biological and thrombolytic properties of proenzyme and active forms of human urokinaseI. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology. Thromb Haemost 1984 52 1 19-23 (Pubitemid 14003802)
94. Schmaier A H. Contact activation: a revision. Thromb Haemost 1997 78 1 101-107 (Pubitemid 27289224)
95. Schousboe I. Factor XIIa activation of plasminogen is enhanced by contact activating surfaces and Zn2+. Blood Coagul Fibrinolysis 1997 8 2 97-104 (Pubitemid 27211722)
96. Levi M, Hack C E., de Boer J P., Brandjes D P., Büller H R., ten Cate J W. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. J Clin Invest 1991 88 4 1155-1160
97. Zeerleder S, Schloesser M, Redondo M et al. Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiencya study on 73 subjects from 14 Swiss families. Thromb Haemost 1999 82 4 1240-1246 (Pubitemid 29473785)
98. Huisman L GM, van Griensven J MT, Kluft C. On the role of C1-inhibitor as inhibitor of tissue-type plasminogen activator in human plasma. Thromb Haemost 1995 73 3 466-471
99. Levi M, Roem D, Kamp A M., de Boer J P., Hack C E., ten Cate J W. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993 69 2 141-146 (Pubitemid 23041184)
100. Römisch J, Feussner A, Vermöhlen S, Stöhr H A. A protease isolated from human plasma activating factor VII independent of tissue factor. Blood Coagul Fibrinolysis 1999 10 8 471-479
101. Römisch J, Vermöhlen S, Feussner A, Stöhr H. The FVII activating protease cleaves single-chain plasminogen activators. Haemostasis 1999 29 5 292-299 (Pubitemid 30207459)
102. Etscheid M, Hunfeld A, König H, Seitz R, Dodt J. Activation of proPHBSP, the zymogen of a plasma hyaluronan binding serine protease, by an intermolecular autocatalytic mechanism. Biol Chem 2000 381 12 1223-1231 (Pubitemid 32094434)
103. Muhl L, Galuska S P., Oörni K et al. High negative charge-to-size ratio in polyphosphates and heparin regulates factor VII-activating protease. FEBS J 2009 276 17 4828-4839
104. Nakazawa F, Kannemeier C, Shibamiya A et al. Extracellular RNA is a natural cofactor for the (auto-)activation of factor VII-activating protease (FSAP). Biochem J 2005 385 Pt 3 831-838 (Pubitemid 40208845)
105. Yamamichi S, Nishitani M, Nishimura N, Matsushita Y, Hasumi K. Polyamine-promoted autoactivation of plasma hyaluronan-binding protein. J Thromb Haemost 2010 8 3 559-566
106. Kannemeier C, Feussner A, Stöhr H A., Weisse J, Preissner K T., Römisch J. Factor VII and single-chain plasminogen activator-activating protease: activation and autoactivation of the proenzyme. Eur J Biochem 2001 268 13 3789-3796 (Pubitemid 32862919)
107. Etscheid M, Beer N, Fink E, Seitz R, Johannes D. The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin. Biol Chem 2002 383 10 1633-1643 (Pubitemid 35282983)
108. Zeerleder S, Zwart B, te Velthuis H et al. A plasma nucleosome releasing factor (NRF) with serine protease activity is instrumental in removal of nucleosomes from secondary necrotic cells. FEBS Lett 2007 581 28 5382-5388 (Pubitemid 350110435)
109. Zeerleder S, Zwart B, te Velthuis H et al. Nucleosome-releasing factor: a new role for factor VII-activating protease (FSAP). FASEB J 2008 22 12 4077-4084
110. Kannemeier C, Al-Fakhri N, Preissner K T., Kanse S M. Factor VII-activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells. FASEB J 2004 18 6 728-730
111. Sedding D, Daniel J M., Muhl L et al. The G534E polymorphism of the gene encoding the factor VII-activating protease is associated with cardiovascular risk due to increased neointima formation. J Exp Med 2006 203 13 2801-2807 (Pubitemid 46026158)
112. Choi-Miura N H., Takahashi K, Yoda M, Saito K, Mazda T, Tomita M. Proteolytic activation and inactivation of the serine protease activity of plasma hyaluronan binding protein. Biol Pharm Bull 2001 24 5 448-452 (Pubitemid 32499464)
113. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994 269 23 15957-15960 (Pubitemid 24209273)
114. Caughman G B., Boackle R J., Vesely J. A postulated mechanism for heparin's potentiation of C1 inhibitor function. Mol Immunol 1982 19 2 287-295 (Pubitemid 12170414)
115. Lennick M, Brew S A., Ingham K C. Kinetics of interaction of C1 inhibitor with complement C1s. Biochemistry 1986 25 13 3890-3898 (Pubitemid 16042518)
116. Nilsson T, Wiman B. Kinetics of the reaction between human C1-esterase inhibitor and C1r or C1s. Eur J Biochem 1983 129 3 663-667 (Pubitemid 13146276)
117. Pixley R A., Schmaier A, Colman R W. Effect of negatively charged activating compounds on inactivation of factor XIIa by Cl inhibitor. Arch Biochem Biophys 1987 256 2 490-498 (Pubitemid 17121960)
118. Rent R, Myhrman R, Fiedel B A., Gewurz H. Potentiation of C1 esterase inhibitor activity by heparin. Clin Exp Immunol 1976 23 264-271
119. Wuillemin W A., te Velthuis H, Lubbers Y T., de Ruig C P., Eldering E, Hack C E. Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J Immunol 1997 159 4 1953-1960 (Pubitemid 127484185)
120. Bos I G., van Mierlo G J., Bleeker W K. et al. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int Immunopharmacol 2001 1 8 1583-1595 (Pubitemid 32622800)
121. Caldwell E E., Andreasen A M., Blietz M A. et al. Heparin binding and augmentation of C1 inhibitor activity. Arch Biochem Biophys 1999 361 2 215-222 (Pubitemid 29391672)
122. Wuillemin W A., Eldering E, Citarella F, de Ruig C P., ten Cate H, Hack C E. Modulation of contact system proteases by glycosaminoglycans. Selective enhancement of the inhibition of factor XIa. J Biol Chem 1996 271 22 12913-12918 (Pubitemid 26175865)
123. Mauron T, Lämmle B, Wuillemin W A. Influence of low molecular weight heparin and low molecular weight dextran sulfate on the inhibition of coagulation factor XIa by serpins. Thromb Haemost 1998 80 1 82-86 (Pubitemid 28353503)
124. Zeerleder S, Caliezi C, van Mierlo G et al. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol 2003 10 4 529-535 (Pubitemid 36890433)
125. Jansen P M., Eisele B, de Jong I W. et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998 160 1 475-484 (Pubitemid 28116764)
126. Caliezi C, Zeerleder S, Redondo M et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002 30 8 1722-1728 (Pubitemid 34879581)
127. Cai S, Dole V S., Bergmeier W et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005 174 10 6462-6466 (Pubitemid 40663841)
128. Liu D, Cai S, Gu X, Scafidi J, Wu X, Davis A E. III. C1 inhibitor prevents endotoxin shock via a direct interaction with lipopolysaccharide. J Immunol 2003 171 5 2594-2601 (Pubitemid 37025571)
129. Liu D, Lu F, Qin G, Fernandes S M., Li J, Davis A E. III. C1 inhibitor-mediated protection from sepsis. J Immunol 2007 179 6 3966-3972
130. Zhang H, Li J, Barrington R A., Liang G, Qin G, Liu D X. An anti-endotoxin peptide that generates from the amino-terminal domain of complement regulatory protein C1 inhibitor. Biochem Biophys Res Commun 2007 359 2 285-291 (Pubitemid 46880503)
131. Liu D, Gu X, Scafidi J, Davis A E. III. N-linked glycosylation is required for c1 inhibitor-mediated protection from endotoxin shock in mice. Infect Immun 2004 72 4 1946-1955 (Pubitemid 38419905)
132. Liu D, Cramer C C., Scafidi J, Davis A E. III. N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A. Infect Immun 2005 73 8 4478-4487 (Pubitemid 41105601)
133. Liu D, Zhang D, Scafidi J, Wu X, Cramer C C., Davis A E. III. C1 inhibitor prevents gram-negative bacterial lipopolysaccharide-induced vascular permeability. Blood 2005 105 6 2350-2355 (Pubitemid 40387030)
134. Horstick G, Heimann A, Götze O et al. Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion. Circulation 1997 95 3 701-708 (Pubitemid 27063048)
135. de Zwaan C, Kleine A H., Diris J H. et al. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J 2002 23 21 1670-1677 (Pubitemid 36287778)
136. Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther 2008 8 8 1225-1240
137. Cichon S, Martin L, Hennies H C. et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006 79 6 1098-1104 (Pubitemid 44853481)
138. Bork K, Schneiders V. Danazol-induced hepatocellular adenoma in patients with hereditary angio-oedema. J Hepatol 2002 36 5 707-709 (Pubitemid 34499414)
139. Cugno M, Nuijens J, Hack E et al. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1990 85 4 1215-1220 (Pubitemid 20123765)
140. Davis A E. III. The pathophysiology of hereditary angioedema. Clin Immunol 2005 114 1 3-9
141. Noga O, Brunnée T, Schäper C, Kunkel G. Heparin, derived from the mast cells of human lungs, is responsible for the generation of kinins in allergic reactions due to the activation of the contact system. Int Arch Allergy Immunol 1999 120 4 310-316 (Pubitemid 30009024)
142. Brunnée T, Reddigari S R., Shibayama Y, Kaplan A P., Silverberg M. Mast cell derived heparin activates the contact system: a link to kinin generation in allergic reactions. Clin Exp Allergy 1997 27 6 653-663 (Pubitemid 27286898)
143. Iwaki T, Castellino F J. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006 95 6 1003-1010 (Pubitemid 43933758)
144. Shariat-Madar Z, Mahdi F, Schmaier A H. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 2002 277 20 17962-17969 (Pubitemid 34967607)
145. Bork K, Siedlecki K, Bosch S, Schopf R E., Kreuz W. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 2000 75 4 349-354 (Pubitemid 30187107)
146. Bork K, Barnstedt S E. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001 161 5 714-718 (Pubitemid 32200225)
147. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006 119 3 267-274 (Pubitemid 43255068)
148. Castro-Magana M, Cheruvanky T, Collipp P J., Ghavami-Maibodi Z, Angulo M, Stewart C. Transient adrenogenital syndrome due to exposure to danazol in utero. Am J Dis Child 1981 135 11 1032-1034 (Pubitemid 12228212)
149. Agostoni A, Bergamaschini L, Martignoni G, Cicardi M, Marasini B. Treatment of acute attacks of hereditary angioedema with C1-inhibitor concentrate. Ann Allergy 1980 44 5 299-301 (Pubitemid 10110161)
150. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992 71 4 206-215
151. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989 83 3 677-682 (Pubitemid 19094619)
152. Cicardi M, Bergamaschini L, Marasini B, Boccassini G, Tucci A, Agostoni A. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci 1982 284 1 2-9 (Pubitemid 12092501)
153. Waytes A T., Rosen F S., Frank M M. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med 1996 334 25 1630-1634 (Pubitemid 26192522)
154. Prematta M, Gibbs J G., Pratt E L., Stoughton T R., Craig T J. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007 98 4 383-388 (Pubitemid 46582131)
155. Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007 119 6 1497-1503 (Pubitemid 46855846)
156. Kunschak M, Engl W, Maritsch F et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion 1998 38 6 540-549 (Pubitemid 28317229)
157. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005 45 11 1774-1784 (Pubitemid 43923905)
158. Zuraw B L., Busse P J., White M et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010 363 6 513-522
159. Craig T J., Levy R J., Wasserman R L. et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009 124 4 801-808
160. Choi G, Soeters M R., Farkas H et al. Recombinant human C1-inhibitor in the treatment of acute angioedema attacks. Transfusion 2007 47 6 1028-1032 (Pubitemid 46802091)
161. Zuraw B, Cicardi M, Levy R J., Nuijens J H. et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010 126 4 821-827